Bionano Genomics (BNGO) Operating Leases (2021 - 2026)

Bionano Genomics' Operating Leases history runs 6 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• In Q1 2026, Operating Leases changed N/A year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (changed N/A YoY), while the FY2025 annual figure was $2.5 million, up 1616.55% from the prior year.
• Operating Leases came in at $2.5 million for Q1 2026 at Bionano Genomics, up from $2.5 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $5.5 million in Q4 2022 to a low of $145000.0 in Q4 2024.
• A 5-year average of $3.7 million and a median of $3.9 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases plunged 95.96% in 2024 and soared 1616.55% in 2025, its largest moves.
• Bionano Genomics' Operating Leases stood at $5.5 million in 2022, then slumped by 34.77% to $3.6 million in 2023, then slumped by 95.96% to $145000.0 in 2024, then jumped by 1616.55% to $2.5 million in 2025, then climbed by 0.72% to $2.5 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $2.5 million, $2.5 million, and $2.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison